Mirum Pharmaceuticals (MIRM) is down about 3.8% in the latest session, with trading chatter refocusing on supply risk tied to a resale offering. The company recently filed for an offering of up to 8.96 million shares of common stock by selling stockholders, a structure that can pressure shares as investors anticipate incremental selling or hedge activity even when the issuer is not raising primary capital. (longbridge.com)

Resale registrations often create a “ceiling” effect in the near term because they increase perceived float availability and can amplify down moves on otherwise quiet news days. With no fresh company press release tied to today’s decline, the move looks consistent with technical/profit-taking dynamics and the market’s sensitivity to potential share supply after a strong multi-month run.

The next major near-term catalyst is Mirum’s upcoming earnings report, which is listed for April 30, 2026 (after market close). Investors will be watching for updates on 2026 commercial execution, any changes to revenue outlook, and pipeline timing, which can quickly re-rate the stock if guidance or milestones surprise. (investing.com)

Operationally, Mirum has highlighted continued commercial growth and clinical progress, including completing enrollment in the Phase 3 EXPAND study of LIVMARLI in additional rare cholestatic liver diseases (announced March 16, 2026). While that headline is generally supportive longer term, it does not directly counter near-term supply concerns when markets are focused on tradable share overhang. (ir.mirumpharma.com)